Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note published on Wednesday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Up 1.8 %

Shares of NASDAQ:EGRX opened at $0.56 on Wednesday. The firm’s 50-day simple moving average is $0.69 and its 200-day simple moving average is $2.78. Eagle Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $6.81.

Institutional Trading of Eagle Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Eagle Pharmaceuticals in the second quarter worth approximately $76,000. XTX Topco Ltd acquired a new stake in Eagle Pharmaceuticals in the second quarter valued at approximately $113,000. Fidelis Capital Partners LLC purchased a new position in Eagle Pharmaceuticals in the 2nd quarter valued at about $71,000. Cubist Systematic Strategies LLC acquired a new stake in Eagle Pharmaceuticals during the 2nd quarter valued at approximately $145,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Eagle Pharmaceuticals in the second quarter worth $65,000. 85.36% of the stock is currently owned by hedge funds and other institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.